Merck Retained Earnings (Accumulated Deficit) 2010-2024 | MRK
Merck retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Merck retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $61.384B, a 7.54% increase year-over-year.
- Merck retained earnings (accumulated deficit) for 2023 were $53.895B, a 11.76% decline from 2022.
- Merck retained earnings (accumulated deficit) for 2022 were $61.081B, a 13.75% increase from 2021.
- Merck retained earnings (accumulated deficit) for 2021 were $53.696B, a 13.37% increase from 2020.
Merck Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$53,895 |
| 2022 |
$61,081 |
| 2021 |
$53,696 |
| 2020 |
$47,362 |
| 2019 |
$46,602 |
| 2018 |
$42,579 |
| 2017 |
$41,350 |
| 2016 |
$44,133 |
| 2015 |
$45,348 |
| 2014 |
$46,021 |
| 2013 |
$39,257 |
| 2012 |
$39,985 |
| 2011 |
$38,990 |
| 2010 |
$37,536 |
| 2009 |
$41,405 |
Merck Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-09-30 |
$61,384 |
| 2024-06-30 |
$60,187 |
| 2024-03-31 |
$56,697 |
| 2023-12-31 |
$53,895 |
| 2023-09-30 |
$57,082 |
| 2023-06-30 |
$54,198 |
| 2023-03-31 |
$62,039 |
| 2022-12-31 |
$61,081 |
| 2022-09-30 |
$59,928 |
| 2022-06-30 |
$58,437 |
| 2022-03-31 |
$56,252 |
| 2021-12-31 |
$53,696 |
| 2021-09-30 |
$51,691 |
| 2021-06-30 |
$48,777 |
| 2021-03-31 |
$48,888 |
| 2020-12-31 |
$47,362 |
| 2020-09-30 |
$51,107 |
| 2020-06-30 |
$49,724 |
| 2020-03-31 |
$48,272 |
| 2019-12-31 |
$46,602 |
| 2019-09-30 |
$45,804 |
| 2019-06-30 |
$45,295 |
| 2019-03-31 |
$44,065 |
| 2018-12-31 |
$42,579 |
| 2018-09-30 |
$42,189 |
| 2018-06-30 |
$41,523 |
| 2018-03-31 |
$41,107 |
| 2017-12-31 |
$41,350 |
| 2017-09-30 |
$43,701 |
| 2017-06-30 |
$45,046 |
| 2017-03-31 |
$44,387 |
| 2016-12-31 |
$44,133 |
| 2016-09-30 |
$46,028 |
| 2016-06-30 |
$45,121 |
| 2016-03-31 |
$45,192 |
| 2015-12-31 |
$45,348 |
| 2015-09-30 |
$45,660 |
| 2015-06-30 |
$45,103 |
| 2015-03-31 |
$45,692 |
| 2014-12-31 |
$46,021 |
| 2014-09-30 |
$39,989 |
| 2014-06-30 |
$40,366 |
| 2014-03-31 |
$39,661 |
| 2013-12-31 |
$39,257 |
| 2013-09-30 |
$39,773 |
| 2013-06-30 |
$39,915 |
| 2013-03-31 |
$40,272 |
| 2012-12-31 |
$39,985 |
| 2012-09-30 |
$40,390 |
| 2012-06-30 |
$39,950 |
| 2012-03-31 |
$39,441 |
| 2011-12-31 |
$38,990 |
| 2011-09-30 |
$38,763 |
| 2011-06-30 |
$38,243 |
| 2011-03-31 |
$37,400 |
| 2010-12-31 |
$37,536 |
| 2010-09-30 |
$39,245 |
| 2010-06-30 |
$40,082 |
| 2010-03-31 |
$40,511 |
| 2009-12-31 |
$41,405 |
| 2009-09-30 |
$47,693 |
| 2009-06-30 |
$45,073 |
| 2009-03-31 |
$44,320 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$244.211B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
